Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
BRUIN Study Response Rates and Patient Population
John summarizes BRUIN trial in heavily pretreated MCL (all previously received a BTKi) with 50% ORR and 13% CR.
Play episode from 14:42
Transcript
